Gapping up
In reaction to strong earnings/guidance: ACPW +13.6%, KN +10.2%, GIG +9.6%, MSTR +7.8%, (announced the appointment of Phong Le as CFO effective on or about August 24, 2015; co also reported earnings), MZOR +6.8%, CMI +4.2%, SIRI +3.4%, RCII +3.1%, STO +2.9%, F +2.5%, VLRS +2.4%, BP +2.3%, MPWR +2.1%, UPS +2%, LH +1.9%, PFE +1.8%, NTLS+1.7%, ORAN +1.4%, CIT +1.3%, DHI +1.3%, WYN +1%, MRK +0.9%
Select metals/mining stocks trading higher: FCX +2.6%, BP +2.2%, MT +2.2%, BHP +2.1%, RIO +1.7%, GOLD +1.2%, NUE +1.1%, AA +1.0%
Fan Favorites showing strength with futures markets: NFLX +1.2%, TSLA +1.1%, AMZN +1%, AAPL +0.7%
Other news: SAEX +17.3% ( awarded a contract for ocean-bottom marine seismic data acquisition services, valued at ~$47 million ), DO +16.3% (still checking, may be in sympathy with STO earnings), SD +8.4% (announces receipt of notice from NYSE regarding continued listing standards - intends to consider available alternatives, potentially including a reverse stock split),JKS +3.8% (signs a three-year RMB3 billion line of credit agreement to support its PV project developments), REGN +3.7% (Regeneron Pharms and Sanofi (SNY) agree to jointly advance PD-1 and other new immuno-oncology antibodies), ASTI +3.4% (disclosed the mutual termination of its May agreement regarding the purchase and sale contract of its Thornton, Colorado headquarters building), SDRL +3.4% (in sympathy with STO earnings), SPWR +3% (announced that it has acquired 1.5 gigawatts of U.S. solar power plant development assets from Australia-based Infigen Energy), HZNP +1.6% (announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma and renal cell carcinoma), ACI +1.4% (announced that for administrative purposes it is postponing the previously announced one-for-ten reverse stock split of common stock), RDS.A +1.4% (in symp with BP), GILD +1.2% (ahead of earnings today)
Analyst comments: ITEK +4.7% (target raised to $29 from $9 at Piper Jaffray), BBRY +3% (upgraded to Equal-Weight from Underweight at Morgan Stanley), AEGR +2.1% (upgraded to Buy from Hold at Jefferies), PHG +1.5% (upgraded to Buy from Hold at Societe Generale), FB +0.6% (target raised to $117 at Axiom Capital ahead of earnings tomorrow afternoon)
In reaction to strong earnings/guidance: ACPW +13.6%, KN +10.2%, GIG +9.6%, MSTR +7.8%, (announced the appointment of Phong Le as CFO effective on or about August 24, 2015; co also reported earnings), MZOR +6.8%, CMI +4.2%, SIRI +3.4%, RCII +3.1%, STO +2.9%, F +2.5%, VLRS +2.4%, BP +2.3%, MPWR +2.1%, UPS +2%, LH +1.9%, PFE +1.8%, NTLS+1.7%, ORAN +1.4%, CIT +1.3%, DHI +1.3%, WYN +1%, MRK +0.9%
Select metals/mining stocks trading higher: FCX +2.6%, BP +2.2%, MT +2.2%, BHP +2.1%, RIO +1.7%, GOLD +1.2%, NUE +1.1%, AA +1.0%
Fan Favorites showing strength with futures markets: NFLX +1.2%, TSLA +1.1%, AMZN +1%, AAPL +0.7%
Other news: SAEX +17.3% ( awarded a contract for ocean-bottom marine seismic data acquisition services, valued at ~$47 million ), DO +16.3% (still checking, may be in sympathy with STO earnings), SD +8.4% (announces receipt of notice from NYSE regarding continued listing standards - intends to consider available alternatives, potentially including a reverse stock split),JKS +3.8% (signs a three-year RMB3 billion line of credit agreement to support its PV project developments), REGN +3.7% (Regeneron Pharms and Sanofi (SNY) agree to jointly advance PD-1 and other new immuno-oncology antibodies), ASTI +3.4% (disclosed the mutual termination of its May agreement regarding the purchase and sale contract of its Thornton, Colorado headquarters building), SDRL +3.4% (in sympathy with STO earnings), SPWR +3% (announced that it has acquired 1.5 gigawatts of U.S. solar power plant development assets from Australia-based Infigen Energy), HZNP +1.6% (announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma and renal cell carcinoma), ACI +1.4% (announced that for administrative purposes it is postponing the previously announced one-for-ten reverse stock split of common stock), RDS.A +1.4% (in symp with BP), GILD +1.2% (ahead of earnings today)
Analyst comments: ITEK +4.7% (target raised to $29 from $9 at Piper Jaffray), BBRY +3% (upgraded to Equal-Weight from Underweight at Morgan Stanley), AEGR +2.1% (upgraded to Buy from Hold at Jefferies), PHG +1.5% (upgraded to Buy from Hold at Societe Generale), FB +0.6% (target raised to $117 at Axiom Capital ahead of earnings tomorrow afternoon)